Liquid Biopsy in Precision Oncology: Expanding Clinical Applications for Molecular Characterization, Disease Monitoring, and Personalized Management of Solid Tumors
DOI:
https://doi.org/10.64784/272Keywords:
Liquid biopsy, Precision oncology, Circulating tumor DNA, ctDNA, Circulating tumor cells, CTCs, Minimal residual disease, Molecular profiling, Solid tumors, Precision medicine, Cancer biomarkers, Treatment monitoring, Tumor heterogeneity, Personalized therapy, Next-generation sequencing.Abstract
Liquid biopsy has rapidly emerged as one of the most promising innovations in precision oncology by providing minimally invasive access to tumor-derived biomarkers throughout the clinical course of cancer. This review analyzes the current evidence regarding the clinical applications of liquid biopsy beyond early cancer detection, emphasizing its role in molecular profiling, therapeutic selection, treatment monitoring, minimal residual disease assessment, identification of resistance mechanisms, and evaluation of tumor heterogeneity in patients with solid tumors. A comprehensive literature review was conducted using major biomedical databases, selecting high-quality publications focused on circulating tumor DNA, circulating tumor cells, extracellular vesicles, circulating RNA, and other emerging biomarkers. The available evidence demonstrates that circulating tumor DNA currently represents the most clinically validated biomarker because of its high analytical performance and increasing incorporation into precision oncology protocols. Liquid biopsy has shown particular utility in lung, colorectal, breast, and prostate cancers, where molecular information directly contributes to personalized treatment decisions. Nevertheless, several barriers continue to limit universal implementation, including high costs, limited molecular infrastructure, methodological variability, and unequal access to advanced genomic technologies, particularly in developing countries. Ongoing technological improvements, international collaboration, and methodological standardization are expected to further expand the clinical applications of liquid biopsy and facilitate its incorporation into routine oncology practice. Overall, liquid biopsy represents a transformative strategy that complements conventional tissue biopsy and supports more personalized, dynamic, and evidence-based management of solid tumors.
References
[1] S. A. Cohen, M. C. Liu, and A. Aleshin, “Practical recommendations for using ctDNA in clinical decision making,” Nature, vol. 619, no. 7970, pp. 259–268, Jul. 2023, doi: 10.1038/s41586-023-06225-y.
[2] Y. Ma, J. Gan, Y. Bai, D. Cao, and Y. Jiao, “Minimal residual disease in solid tumors: An overview,” Frontiers of Medicine, vol. 17, no. 4, pp. 573–589, 2023, doi: 10.1007/s11684-023-1018-6.
[3] C. Abbosh et al., “Minimal residual disease as a target for liquid biopsy in patients with solid tumours,” Nature Reviews Clinical Oncology, vol. 21, 2024, doi: 10.1038/s41571-024-00967-y.
[4] P. Sidaway, “New data confirm clinical utility of ctDNA,” Nature Reviews Clinical Oncology, vol. 20, p. 63, 2023, doi: 10.1038/s41571-022-00716-z.
[5] G. Siravegna, S. Marsoni, S. Siena, and A. Bardelli, “Integrating liquid biopsies into the management of cancer,” Nature Reviews Clinical Oncology, vol. 14, no. 9, pp. 531–548, 2017.
[6] A. Bardelli and K. Pantel, “Liquid biopsies, what we do not know (yet),” Cancer Cell, vol. 31, no. 2, pp. 172–179, 2017.
[7] M. Ignatiadis, G. W. Sledge Jr., and S. S. Jeffrey, “Liquid biopsy enters the clinic—Implementation issues and future challenges,” Nature Reviews Clinical Oncology, vol. 18, no. 5, pp. 297–312, 2021.
[8] C. Alix-Panabières and K. Pantel, “Liquid biopsy: From discovery to clinical application,” Cancer Discovery, vol. 11, no. 4, pp. 858–873, 2021.
[9] J. C. M. Wan et al., “Liquid biopsies come of age: Towards implementation of circulating tumour DNA,” Nature Reviews Cancer, vol. 17, no. 4, pp. 223–238, 2017.
[10] K. Pantel and C. Alix-Panabières, “Liquid biopsy and minimal residual disease—Latest advances and implications for cure,” Nature Reviews Clinical Oncology, vol. 16, pp. 409–424, 2019.
[11] M. Diehl et al., “Circulating mutant DNA to assess tumor dynamics,” Nature Medicine, vol. 14, no. 9, pp. 985–990, 2008.
[12] J. Tie et al., “Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer,” Science Translational Medicine, vol. 8, no. 346, Art. no. 346ra92, 2016.
[13] J. D. Merker et al., “Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review,” Journal of Clinical Oncology, vol. 36, no. 16, pp. 1631–1641, 2018.
[14] G. R. Oxnard et al., “Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA,” Clinical Cancer Research, vol. 20, no. 6, pp. 1698–1705, 2014.
[15] C. Bettegowda et al., “Detection of circulating tumor DNA in early- and late-stage human malignancies,” Science Translational Medicine, vol. 6, no. 224, Art. no. 224ra24, 2014.
[16] C. Alix-Panabières and K. Pantel, “Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy,” Cancer Discovery, vol. 6, no. 5, pp. 479–491, 2016.
[17] J. C. M. Wan et al., “Liquid biopsies come of age: Towards implementation of circulating tumour DNA,” Nature Reviews Cancer, vol. 17, no. 4, pp. 223–238, 2017.
[18] L. Keller and K. Pantel, “Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells,” Nature Reviews Cancer, vol. 19, no. 10, pp. 553–567, 2019.
[19] D. R. Gandara et al., “Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab,” Nature Medicine, vol. 24, no. 9, pp. 1441–1448, 2018.
[20] American Society of Clinical Oncology, “Circulating tumor DNA testing in solid tumors and lymphoma: ASCO guideline,” JCO Oncology Practice, 2026, doi: 10.1200/OP-26-00311.
